Founded in 2025, Innofend is a biotechnology company originating from Tampere University that is developing a next-generation vaccine platform to prevent diseases caused by enteroviruses. The company aims to develop broadly protective vaccine solutions that address the significant global health burden posed by enteroviruses.
Innofend’s technology is based on research conducted at Tampere University in enteroviruses, vaccine development and viral biology. The company is developing a vaccine platform designed to provide protection against multiple enteroviruses using a single technological approach.
Impact
Innofend is developing new ways to prevent enterovirus infections and their potentially severe consequences. The company’s solutions could improve access to vaccines and broaden protection against viruses for which comprehensive preventive measures are not currently available.
The company strengthens Finland’s biotechnology expertise and supports the development of novel vaccine innovations for international markets. At the same time, it promotes the translation of research into solutions that address healthcare and public health needs.
Background
Innofend builds on research conducted at Tampere University in enteroviruses, viral biology and vaccine development. The company demonstrates how university research can lead to new solutions for preventing infectious diseases worldwide.